| 血管内皮抑素联合GP方案治疗转移性三阴性乳腺癌的临床研究 |
| |
| 引用本文： | 陆颖,黄海欣,李桂生. 血管内皮抑素联合GP方案治疗转移性三阴性乳腺癌的临床研究[J]. 中国肿瘤临床, 2012, 39(23): 1946-1948,1955. DOI: 10.3969/j.issn.1000-8179.2012.23.019 |
| |
| 作者姓名： | 陆颖 黄海欣 李桂生 |
| |
| 作者单位： | 广西医科大学第四附属医院肿瘤科（广西壮族自治区柳州市545005） |
| |
| 摘 要： | 目的 对比重组人血管内皮抑素(YH-16)联合GP方案与GP方案在治疗转移性三阴性乳腺癌中的有效性和安全性。 方法 55例转移性乳腺癌患者既往均经病理学诊断为三阴性浸润性导管癌, 均接受过紫杉类及蒽环类药物治疗。随机分为观察组及对照组, 其中观察组27例, 给予重组人血管内皮抑素联合GP方案治疗(重组人血管内皮抑素15 mg静脉滴注d1~14, 吉西他滨1 000mg/m2静脉滴注d1, 8;顺铂40mg/m2静脉滴注d1, 2);对照组28例, 仅给予GP方案化疗, 每3周为1个周期, 每2个周期评价疗效。 结果 55例患者均可评价疗效, 观察组(27例): 完全缓解(CR)3例(11.1%), 部分缓解(PR)9例(33.3%), 客观有效率(CR+PR)44.4%;对照组(28例): CR 1例(3.5%), PR 9例(32.1%), 客观有效率(CR+PR)35.7%。两组中位疾病进展时间分别为7.0、5.2个月, 无疾病进展生存比较有显著性差异(P=0.001)。不良反应主要为胃肠道反应及骨髓抑制, 两组比较无显著性差异(P > gt; 0.05)。 结论 重组人血管内皮抑素联合GP方案治疗转移性三阴性乳腺癌具有协同作用, 未增加不良反应, 可延长中位疾病进展时间, 值得进一步研究。
|
| 关 键 词： | 乳腺癌 化疗 血管内皮抑素 吉西他滨 顺铂 |
| 收稿时间： | 2011-02-09 |
Clinical Study of the Combination of Endostar and GP Regimen in the Treatment of Metastatic TNBC |
| |
| Ying LU,Haixin HUANG,Guisheng LI. Clinical Study of the Combination of Endostar and GP Regimen in the Treatment of Metastatic TNBC[J]. Chinese Journal of Clinical Oncology, 2012, 39(23): 1946-1948,1955. DOI: 10.3969/j.issn.1000-8179.2012.23.019 |
| |
| Authors: | Ying LU Haixin HUANG Guisheng LI |
| |
| Affiliation: | Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545005, China |
| |
| Abstract: | Objective This study aims to compare the efficacy and the toxicity of YH-16+GP and GP regimens for metastatic triple-negative breast cancer (TNBC). Methods Fifty-five metastatic TNBC patients with anthracycline and taxane resistance were randomly divided into two groups and received YH-16+GP or GP treatment. The YH-16+GP regimen was composed of YH-16 (15 mg dl,-14), gemcitabine (1000 mg/m2 dl, 8), and cisplatin (40 mg/m2 dl, 2), administered for 21 days per cycle. The GP regimen only included gemcitabine and cisplatin. The clinical responses of the patients were assessed after two cycles of chemotherapy. Results In the YH-16+GP group, 3 cases with complete response (CR) (11.1%) and 9 cases with partial response (PR) (33.3%) were identified. The total response rate (CR+PR) was 44.4%. In the GP group, 1 CR case (3.5%) and 9 PR cases (32.1%), with total response rate (CR+PR) of 35.7%, were recorded. The median time for the progression of the disease was 7.0 and 5.2 months, respectively, for the two groups. Significant differences in disease-free survival rate were found between the two groups (P=0.001). Drug-related toxicity was denoted by gastrointestinal tract reaction and bone marrow depression, but no significant differences were found between the two groups (P > 0.05). Conclusion The YH-16+GP regimen has better short-term efficacy, has acceptable toxicity, and improves the TTP regimen. Thus, the YH-16+GP regimen can be considered a salvage regimen for metastatic TNBC. |
| |
| Keywords: | |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
